|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
1
|
|
pubmed:dateCreated |
2007-8-3
|
|
pubmed:abstractText |
The purpose of treatment in patients with advanced and metastatic esophageal cancer is to improve symptoms and maintain quality of life. Recently, the regimen including epirubicin, cisplatin, and 5-FU (ECF) has been used with protracted venous infusion (PVI), and has been reported to be an effective treatment for advanced and metastatic esophagogastric cancer. However, complications and the inconvenience associated with PVI cannot be justified for the treatment of advanced esophageal cancer. Therefore, we provided treatment with oral UFT and leucovorin instead of 5-FU PVI to improve convenience and catheter related complications.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:issn |
1357-0560
|
|
pubmed:author |
pubmed-author:ChoiChul WonCW,
pubmed-author:ChoiIn KeunIK,
pubmed-author:KimByung SooBS,
pubmed-author:KimJun SukJS,
pubmed-author:KimSeok JinSJ,
pubmed-author:KimYeul HongYH,
pubmed-author:OhSang CheulSC,
pubmed-author:ParkKyong HwaKH,
pubmed-author:SeoHee YunHY,
pubmed-author:SeoJae HongJH,
pubmed-author:ShinSang WonSW,
pubmed-author:SungHwa JungHJ
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
24
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
33-7
|
|
pubmed:meshHeading |
pubmed-meshheading:17673809-Adenocarcinoma,
pubmed-meshheading:17673809-Administration, Oral,
pubmed-meshheading:17673809-Adult,
pubmed-meshheading:17673809-Aged,
pubmed-meshheading:17673809-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:17673809-Carcinoma, Squamous Cell,
pubmed-meshheading:17673809-Cisplatin,
pubmed-meshheading:17673809-Epirubicin,
pubmed-meshheading:17673809-Esophageal Neoplasms,
pubmed-meshheading:17673809-Female,
pubmed-meshheading:17673809-Humans,
pubmed-meshheading:17673809-Leucovorin,
pubmed-meshheading:17673809-Male,
pubmed-meshheading:17673809-Maximum Tolerated Dose,
pubmed-meshheading:17673809-Middle Aged,
pubmed-meshheading:17673809-Prognosis,
pubmed-meshheading:17673809-Survival Rate,
pubmed-meshheading:17673809-Tegafur,
pubmed-meshheading:17673809-Treatment Outcome,
pubmed-meshheading:17673809-Uracil
|
|
pubmed:year |
2007
|
|
pubmed:articleTitle |
Epirubicin, cisplatin, oral UFT, and leucovorin combination chemotherapy in advanced and metastatic esophageal cancer.
|
|
pubmed:affiliation |
Department of Internal Medicine, Division of Hematology/Oncology, College of Medicine, Korea University, Seoul, Korea.
|
|
pubmed:publicationType |
Journal Article,
Multicenter Study
|
